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Introduction
Coronary heart disease is the leading cause of death worldwide 
[1]. The most effective therapeutic intervention for reducing infarct 
size associated with myocardial ischemic injury is timely and effective 
reperfusion of blood flow back to the heart tissue by percutaneous 
coronary intervention. However, the reperfusion of blood itself can 
induce additional cardiomyocyte death that can account for up to 
50% of the final infarct size [2]. Remarkably, after several decades of 
preclinical and clinical studies, there is still no effective therapy to 
limit reperfusion-induced tissue death and improve post-reperfused 
cardiac function. Consequently, there is a great need to identify the 
mechanism(s) responsible for myocardial ischemia/reperfusion injury. 
Ischemia/reperfusion injury is initiated in part by endothelial 
dysfunction, which occurs within 5 min of reperfusion. It is characterized 
by an increase in reactive oxygen species leading to endothelial nitric 
oxide synthase uncoupling, which in turn causes more reactive oxygen 
species production and limited endothelial-derived Nitric Oxide 
(NO) bioavailability [2-4]. The reduced NO bioavailability leads to 
compromised blood flow during reperfusion and increased leukocyte-
endothelial interactions, which will exacerbate tissue damage. The time 
course of endothelial dysfunction in myocardial ischemia/reperfusion 
is similar to other vascular beds, such as hind limb ischemia/reperfusion 
and splanchnic ischemia/reperfusion [5,6]. The significance of this 
commonality is that compounds that attenuate endothelial dysfunction 
in the heart could be applied to other vascular beds such as pulmonary, 
kidney, liver, mesenteric and limb circulation. Therefore, this could 
be clinically applied to prevent organ damage in various ischemia/
reperfusion injury settings, such as organ transplantation, circulatory 
shock, prolonged tourniquet use and coronary bypass/balloon 
angioplasty. 
In order to understand endothelial dysfunction during ischemia/
Apocynin Exerts Dose-Dependent Cardioprotective Effects by Attenuating 
Reactive Oxygen Species in Ischemia/Reperfusion
Qian Chen, Woodworth Parker C, Issachar Devine, Regina Ondrasik, Tsion Habtamu, Kyle D Bartol, Brendan Casey, Harsh Patel, William 
Chau, Tarah Kuhn, Robert Barsotti and Lindon Young*
Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, USA
Abstract
Ischemia/reperfusion results in cardiac contractile dysfunction and cell death partly due to increased reactive oxygen 
species and decreased endothelial-derived nitric oxide bioavailability. NADPH oxidase normally produces reactive 
oxygen species to facilitate cell signalling and differentiation; however, excessive release of such species following 
ischemia exacerbates cell death. Thus, administration of an NADPH oxidase inhibitor, apocynin, may preserve 
cardiac function and reduce infarct size following ischemia. Apocynin dose-dependently (40 μM, 400 μM and 1 
mM) attenuated leukocyte superoxide release by 87 ± 7%. Apocynin was also given to isolated perfused hearts 
after ischemia, with infarct size decreasing to 39 ± 7% (40 μM), 28 ± 4% (400 μM; p < 0.01) and 29 ± 6% (1 
mM; p < 0.01), versus the control’s 46 ± 2%. This decrease correlated with improved final post-reperfusion left 
ventricular end-diastolic pressure, which decreased from 60 ± 5% in control hearts to 56 ± 5% (40 µM), 43 ± 4% 
(400 μM; p < 0.01) and 48 ± 5% (1 mM; p < 0.05), compared to baseline. Functionally, apocynin (13.7 mg/kg, 
I.V.) significantly reduced H2O2 by nearly four-fold and increased endothelial-derived nitric oxide bioavailability by 
nearly four-fold during reperfusion compared to controls (p < 0.01), which was confirmed in in vivo rat hind limb 
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contractile dysfunction and infarct size by inhibiting reactive oxygen species release from NADPH oxidase.
*Corresponding author: Lindon Young, Department of Bio-Medical Sciences, 
Philadelphia College of Osteopathic Medicine (PCOM), 4170 City Avenue, Philadelphia, 
USA, Tel: 2158716832; Fax: 2158716869; E-mail: Lindonyo@PCOM.edu
Received February 16, 2016; Accepted February 24, 2016; Published March 01, 
2016
Citation: Chen Q, Parker WC, Devine I, Ondrasik R, Habtamu T, et al. (2016) 
Apocynin Exerts Dose-Dependent Cardioprotective Effects by Attenuating Reactive 
Oxygen Species in Ischemia/Reperfusion. Cardiovasc Pharm Open Access 5: 176. 
doi:10.4176/2329-6607.1000176
Copyright: © 2016 Chen Q, et al. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
reperfusion, we established an in vivo rat hindlimb ischemia/
reperfusion injury model that directly measures reactive oxygen species 
levels in blood (i.e., hydrogen peroxide [H2O2]) and NO in real-time 
[4,7,8] from both femoral veins (with one limb subjected to ischemia/
reperfusion and the other serving as a sham control). H2O2 is an indirect 
index of superoxide (SO) release because SO dismutase rapidly, within 
seconds, converts SO to H2O2; this process is enhanced under low pH 
conditions [9,10]. Our hind limb ischemia/reperfusion injury model 
is appropriate to measure H2O2 and NO blood levels during ischemia/
reperfusion because the direct measurements are not feasible in the 
coronary circulation of the isolated perfused rat heart model. We found 
that an inverse relationship exists between blood H2O2 and NO levels 
in ischemia/reperfusion . Greater production of H2O2 and reduction 
of NO during reperfusion in hind limb ischemia/reperfusion closely 
correlates with a greater degree of post-reperfused cardiac dysfunction 
in myocardial ischemia/reperfusion [4,7,8].Therefore, quantifying 
blood reactive oxygen species release and NO levels in real-time during 
reperfusion is important to determine the initiating sources of reactive 
oxygen species in ischemia/reperfusion and to develop potential 
treatment strategies for ameliorating reperfusion injury. 
Although clinical trials suggest non-selective antioxidants do not 
effectively attenuate reperfusion injury, this may be due to lack of 
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specifically targeting the source of oxidative stress. Four enzymatic 
sources principally contribute to oxidative stress (i.e., reactive oxygen 
species) during reperfusion: NADPH oxidase, xanthine oxidase, 
uncoupled eNOS, and the mitochondrial electron transport chain. 
NADPH oxidases comprise a family of enzymes that initiates and 
recruits the other three sources as follows [11]: 1. NADPH oxidase 2 
(Nox2) naturally produces SO/H2O2 upon the assembly of the cytosolic 
subunits (i.e., rac, p67phox, p47phox, and p40phox) with, the membrane 
subunits (i.e., p22phox and gp91phox); 2. It is expressed in many cells in the 
heart, such as vascular endothelium and cardiac myocytes, and is the 
principle source of SO release in leukocytes; 3. SO/H2O2 release from 
activated NADPH oxidase can open mitochondrial ATP-dependent 
potassium channels and/or mitochondria permeability transition pores, 
which further lead to mitochondrial matrix alkalization, mitochondrial 
electron transport chain uncoupling, and SO production [12]; 4. 
Overproduction of SO/H2O2 will also promote the transformation 
of xanthine dehydrogenase into xanthine oxidase [13,14]; 5. SO can 
quench NO to form peroxynitrite anion, which in turn can promote 
eNOS uncoupling via the oxidation of the essential eNOS co-factor 
tetrahydrobiopterin (BH4) to dihydrobiopterin (BH2) [15]. It has 
been found in vitro that the increased ratio of BH2 to BH4 facilitates 
BH2 binding at the eNOS oxygenase domain, allowing eNOS to use 
molecular oxygen to produce SO and, subsequently, H2O2 in blood 
[16]. 6. Reactive oxygen species release during reperfusion serves as a 
key initiating factor that triggers the release of a major inflammatory 
cytokine, tumor necrosis factor, alpha (TNFα), within the first 15 min 
of reperfusion [12,17-20] (Figure 1).
Consequently, inhibition of Nox2 may be an effective strategy to 
prevent the downstream sequelae of reperfusion injury and salvage 
heart tissue during myocardial infarction or organ transplantation. 
Previous studies show apocynin, an alkaloid derived from Apocynum 
cannabinum, is a selective Nox2 assembly inhibitor that may oxidize 
the thiols in NADPH oxidase. Moreover, apocynin may be a prodrug 
and thus needs to be activated by peroxidase-mediated oxidation to 
diapocynin, its active oxidizing form, which is illustrated in Figure 2. 
Specifically, the effects of apocynin oxidize the cysteine-196 position 
of p47phox, a cytosolic component of NADPH oxidase that is activated 
via phosphorylation by protein kinase C, which, in turn, inhibits the 
association of the p22phox membrane subunit component of NADPH 
oxidase and, therefore inhibit Nox2 assembly and subsequent SO 
release, thereby decreased oxidative stress and tissue damage [21,22]. 
We hypothesize that administration of selective NADPH oxidase 
inhibitors, such as apocynin, will dose-dependently attenuate 
blood H2O2 and augment NO bioavailability in hindlimb ischemia/
reperfusion, and will decrease SO release from leukocytes and reduce 
infarct size/area-at-risk in ischemia/reperfusion hearts, and thus 
improving post-reperfused cardiac function. 
Methods
Animals
All animal procedures were approved by the Institutional Animal 
Care and Use Committee at PCOM for care and use of animals. Male 
Sprague Dawley (SD) rats (275-325 g; Ace Animals, Boyertown, PA)
Measurement of SO release from rat PMNs
The SO release from Poly Morphonuclear Leukocytes (PMNs) 
was measured spectrophotometrically (model 260 Gilford, Nova 
Biotech; El Cajon, CA) by the reduction of ferricytochrome c as 
previously described [23]. The PMNs (5  ×  106) were resuspended in 
450 μl PBS and incubated with ferricytochrome c (100 µM, Sigma 
Chemical) in a total volume of 900 μl PBS in the presence or absence 
of varying concentrations of apocynin (MW  =  166 g/mol; Sigma 
 
Figure 1: Ischemia/reperfusion insults leads to mitochondria damage releasing O2- to initiate the oxidation process of BH4 to BH2 causing the uncoupling of eNOS. 
Meanwhile cytokine mediated receptor stimulation activates protein kinase C which in turn phosphorylates NAPDH and eNOS to produce O2
- that also leads to the 
increase of oxidation of BH4 to BH2 causing more uncoupling of eNOS. Collectively these sources of reactive oxygen species reduce the amount of nitric oxide 
available. Modified from Wilkinson et al. and Schmidt and Alp [15,38].
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ischemia and 45 min reperfusion. The changes in H2O2 or NO release 
(in pA) during ischemia/reperfusion are expressed as relative change 
to baseline (initial) readings. Thereafter, the values were converted to 
the concentration of H2O2 (μM) or NO (nM) after correction to the 
respective calibration curves. The values recorded from the femoral 
vein of the ischemia/reperfusion limb were subtracted from the values 
of the sham limb to yield a net difference and were recorded every 5 
min continuously on time course graphs.
Statistical analysis
All data in the text and figures are presented as means ±  S.E.M. 
The data were analyzed by analysis of variance using post hoc analysis 
with the Student-Newman-Keuls test for PMN SO release and cardiac 
function/infarct size/area-at-risk and Student’s t-test for the hindlimb 
ischemia/reperfusion data. Probability values of ≤ 0.05 are considered 
to be statistically significant.
Results
Apocynin dose-dependently decreased fMLP-induced PMN 
SO release
PMNs release SO principally by activating NADPH oxidase. fMLP 
peptide activates PMN chemotactic receptor to generate the second 
messengers Ca++ and DAG that activates protein kinase C isoforms to 
phosphorylate serine residues on p47phox to promote NADPH oxidase 
assembly at the PMN membrane to generate SO release (Figure 1). We 
found that apocynin exhibited dose-dependent reduction in fMLP-
stimulated PMN SO release (Figure 3). Apocynin at 40 μM had no 
effect on PMN SO, whereas 400 μM and 1 mM significantly inhibited 
this response by 64 ± 7 and 87 ± 7%, respectively. The data generated 
from this assay was used to test a similar dose range of apocynin in the 
isolated rat heart ischemia/reperfusion experiments.
Apocynin attenuated post-reperfused cardiac dysfunction 
and infarct size and area-at-risk
Apocynin given at reperfusion significantly does-dependently 
attenuated ischemia/reperfusion induced cardiac contractile 
dysfunction and improved post-reperfused left ventricular developed 
pressure to 60 ± 6% (40 µM; p < 0.05) and 74 ± 3.6% (400 μM; p < 0.01) 
and 66 ± 3.6% (1 mM; p < 0.01) of baseline at 45 min post-reperfusion 
compared to control ischemia/reperfusion hearts that only recovered 
to 47 ± 5% of baseline values for left ventricular developed pressure 
(Table 1). Apocynin (400 μM and 1 mM) significantly reduced post-
Chemical), 40 µM, 400 µM, or 1 mM, respectively, for 15 min at 37°C 
in spectrophotometric cells. The PMNs were stimulated with 1 μM 
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP, MW  =  437 
g/mol; Calbiochem) in a final reaction volume of 1.0 ml. Absorbance 
at 550 nm was measured every 30 sec for up to 90 sec for fMLP (peak 
response), and the change in absorbance (SO release) from PMNs was 
determined relative to time 0. The dose-response curve of apocynin 
on PMN SO release was used to determine a dose range that may be 
effective in myocardial ischemia/reperfusion experiments.
Isolated rat heart preparation
SD rats were injected with pentobarbital sodium 60 mg/kg and 
sodium heparin (1,000 U) Intra peritoneally (I.P.); after which the hearts 
were rapidly excised. The plasma was collected from the abdominal 
aorta of the same rat from which the heart was isolated for each cardiac 
perfusion experiment in order to be used infusion at the beginning of 
reperfusion [24]. The isolated rat heart was cannulated via the aorta 
onto a perfusion needle and immersed in a water-jacketed reservoir 
that contained 160 ml of Krebs’ buffer. The hearts were perfused with 
a modified Krebs’ buffer (in mmol/l: 17.0 dextrose, 120.0 NaCl, 25.0 
NaHCO3, 2.5 CaCl2, 0.5 EDTA, 5.9 KCl, and 1.2 MgCl2) maintained at 
37oC at a constant pressure of 80 mmHg and aerated with 95% O2-5% 
CO2 to keep the pH at 7.3-7.4. A side arm in the perfusion line proximal 
to the heart inflow cannula allowed infusion of plasma (control hearts) 
or plasma containing apocynin (40 µM, 400 µM and 1 mM). Coronary 
flow was monitored by a flowmeter (T106, Transonic Systems, Inc., 
Ithaca, NY). Left ventricular developed pressure, which is the left 
ventricular end-systolic pressure minus left ventricular end-diastolic 
pressure, the maximal and minimal rate of left ventricular developed 
pressure (+ dP/dtmax and – dP/dtmin, respectively) and heart rate were 
monitored using a pressure transducer (SPR-524, Millar Instruments, 
Inc., Houston, TX) positioned in the left ventricular cavity and 
recorded using a Powerlab Station acquisition system (ADInstruments, 
Grand Junction, CO). Coronary flow, left ventricular developed 
pressure, +  dP/dtmax, –  dP/dtmin and heart rate were measured every 
5 min for 15 min to obtain baseline measurements. After baseline, 
global ischemia was induced for 30 min by stopping the flow of Krebs’ 
buffer. Hearts were infused at the beginning of reperfusion with plasma 
or plasma containing apocynin at a rate of 1 ml/min for 5 min. Data 
continued to be recorded every 5 min for the 45 min reperfusion. At 
the end of the experiment, the infarct area and area-at-risk (i.e. entire 
heart) was visualized and measured by treating the tissue with 1% 
2,3,5-triphenyltetazolium (TTC), as previously described [25].
Hind limb ischemia/reperfusion in vivo procedure
We measured blood H2O2/NO release in real-time from sensors 
placed in the femoral veins of male SD rats anesthetized with 
sodium pentobarbital (60 mg/kg, I.P. for induction and 30 mg/kg IP 
for maintenance). Thereafter, one limb was subjected to ischemia/
reperfusion, while the other limb was used as a non-ischemic sham 
control in the same rat. The H2O2 or NO microsensors (100 µm, World 
Precision Instruments [WPI] Inc., Sarasota, FL) were connected to a 
free radical analyzer (Apollo 4000, WPI Inc.) and inserted into a 24 
gauge catheter placed inside each femoral vein, as previously described 
by Perkins et al. [8] and reviewed by Young et al. [26]. Ischemia in 
one hind limb was induced by clamping the femoral artery/vein for 
20 min followed by 45 min of reperfusion. Apocynin (13.7 mg/kg 
prepared in saline;  ~  1 mM in blood) or saline (non-drug control 
group) was administered at the beginning of reperfusion as a bolus via 
the jugular vein. We continuously recorded and collected the H2O2 or 
NO release data at 5 min intervals during a 15 min baseline, 20 min 
Figure 2: Schematic showing the inactive and active forms of NADPH 
oxidase. Red-line denotes the area of inhibition performed by apocynin. 
Adapted from Wilkinson et al. [38].
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reperfused left ventricular end-diastolic pressure compared to control 
ischemia/reperfusion values by 17 ± 3.8 (p < 0.01) and 12 ± 4.9 mmHg 
(p < 0.05). Whereas, apocynin 40 μM did not significantly affect this 
parameter compared to ischemia/reperfusion controls (Table 1). 
Similarly, apocynin exhibited a dose-dependent effect on reducing 
infarct size/area-at-risk, as illustrated in Figure 4. 
Other cardiac function parameters are illustrated in Table 1. Of 
interest, dose-dependent effects of apocynin were also observed for 
+ dP/dtmax. Specifically, apocynin improved post-reperfused + dP/dtmax 
by 48  ±  6% (40 µM), 63  ±  4% (400 µM; p  <  0.01), and 56  ±  4% (1 
mM; p < 0.01) at 45 min reperfusion compared to control ischemia/
reperfusion hearts that only recovered to 38 ± 4%. Sham hearts (n = 6) 
were not subjected to ischemia/reperfusion and maintained cardiac 
function parameters and flow by > 90% and had < 5% infarct size/area-
at- risk throughout the experimental time-course (data not shown).
Apocynin reduced blood H2O2 levels
Apocynin given I.V. (13.7 mg/kg) at the beginning of reperfusion 
decreased H2O2 in hind limb ischemia/reperfusion models compared 
to saline controls (Figure 5). Specifically, in saline control trails, H2O2 
peaked up to 2.5 μM during the first 5 min of reperfusion. Thereafter, 
the levels of H2O2 dropped to 1μM in blood, a concentration that was 
maintained throughout the reperfusion period. By contrast, apocynin-
treated animals H2O2 had an increase to nearly 5 μM during the first 
five minutes of reperfusion; however, the level decreased, up to 4-fold, 
compared to saline control trials throughout the experimental time 
course. Of note, the decreased H2O2 levels were significantly different 
compared to saline controls between 20 and 45 min.
Apocynin increased blood NO levels
Apocynin given I.V. (13.7 mg/kg) at the beginning of reperfusion 
increased NO in hind limb ischemia/reperfusion models compared to 
saline controls (Figure 6). Blood NO levels in saline controls a brief 
transiently increased to ~ 30 nM during the first 5 min of reperfusion; 
however, the levels decreased to approximately 50 nM, compared 
to baseline, at the end of the experimental time course. Conversely, 
apocynin-treated animals’ blood NO levels significantly increased 
to  ~  180 nM, as compared to baseline, during the first 5 min of 






Initial LVDP (mmHg) 87 ± 3.7 92 ± 3.1 92 ± 3.1 94 ± 3.4
Final LVDP  (mmHg) 41 ± 4.6 55 ± 6* 68 ± 3.4** 62 ± 3.4**
Initial LVESP (mmHg) 98 ± 3.9 105 ± 3.2 103 ± 3.5 104 ± 3.8
Final LVESP (mmHg) 101 ± 5.8 111 ± 6.4 111 ± 4 111 ± 4.6
Initial LVEDP (mmHg) 11 ± 0.6 14 ± 0.7 11 ± 0.8 10 ± 0.9
Final LVEDP(mmHg) 60 ± 5.2 56 ± 4.8 43 ± 3.8** 48 ± 4.9*
Initial + dP/dtmax (mmHg/sec) 2336 ± 73 2331 ± 56 2284 ± 69 2385 ± 101
Final + dP/dtmax (mmHg/sec) 882 ± 104 1121 ± 135 1446 ± 89** 1342 ± 95**
Initial dP/dtmin (mmHg/sec) -1554 ± 72 -1585 ± 45 -1585 ± 68 -1617 ± 112
Final dP/dtmin (mmHg/sec) -745 ± 57 -793 ± 99 -1091 ± 58** -928 ± 45
Initial coronary flow (ml/min) 16.5 ± 1.3 19.1 ± .0.9 21 ± 1.3 17 ± 1.5
Final coronary flow (ml/min) 7.8 ± 0.57 10.5 ± 1.1 11.8 ± 1.4 8.9 ± 0.84
Initial Heart Rate (BPM) 279 ± 14.3 283 ± 16.5 273 ± 6.7 273 ± 11.1
Final Heart Rate (BPM) 239 ± 16.9 259 ± 13.1 245 ± 8.5 239 ± 9.6
*p < 0.05, **p < 0.01 versus control I/R final cardiac function parameters
I/R = Ischemia/Reperfusion
LVDP = Left Ventricular Developed Pressure
LVESP = Left Ventricular End-Systolic Pressure
LVEDP = Left Ventricular End-Diastolic Pressure
Table 1: Cardiac function parameters among different experimental groups.
 
 
Figure 3: fMLP (1 μM)-induced SO release in PMNs. The peak response 
in SO release (90 sec). Apocynin (ApoC) (400 µM and 1 mM) significantly 
attenuated fMLP-induced SO release by 64 ± 7% and 87 ± 7%, respectively, 
compared to fMLP (**P < 0.01).
reperfusion. These levels quickly dropped to  ~  50 nM between 10 
and 20 min post-reperfusion, but at 20 min post-reperfusion began 
to significantly rise to  ~  130 nM throughout the remainder of the 




The major findings of this study are as follows: 1. Apocynin dose-
dependently attenuated fMLP-induced leukocyte SO release by 64 
± 7% and 87 ± 7% at 400 μM and 1mM, compared to untreated controls 
(p < 0.01); 2. In isolated perfused hearts, apocynin attenuated infarct 
size/area-at-risk by 39 ± 7% (40 μM), 28 ± 4% (400 μM; p < 0.01) and 
29 ± 6% (1 mMp < 0.01), compared to control ischemia/reperfusion 
hearts that had an infarct size/area-at-risk of 46 ±  2%; 3. Apocynin 
decreased left ventricular end-diastolic pressure to 56 ± 5% (40 μM), 
43 ± 4% (400 μM; p < 0.01) and 48 ± 5% (1 mM; p < 0.05) compared 
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reperfusion in part through activation of TNFα receptors that in 
turn activate protein kinase C [20,27,28]. Activated protein kinase C 
isoforms (e.g., alpha, beta II and zeta) phosphorylate serine residues 
on cytosolic p47phox, which is primarily expressed in leukocytes and 
vascular endothelium, to promote assembly and activation of NADPH 
oxidase [27,29] leading to the production of SO (Figure 1). It has been 
indicated that NADPH oxidase activation is the initial source of SO, 
that in part mediates mitochondrial potassium ATP channel opening 
and release of reactive oxygen species during angiotensin II induced 
preconditioning [30]. It is well-known that transient mitochondrial 
potassium ATP channel opening is important to induce preconditioning 
in the heart to reduce infarct size [31]. However, prolonged opening 
of this mitochondrial channel throughout prolonged ischemia 
(i.e., 30 min) and during reperfusion does not reduce infarct size 
compared to untreated I/R controls [32]. Consequently, prolonged 
opening of mitochondria potassium ATP channels during ischemia 
and reperfusion may contribute to oxidative stress during ischemia/
reperfusion and in turn further oxidize BH4 to BH2 to promote eNOS 
uncoupling and further reactive oxygen species release (Figure 1). 
Regarding NADPH oxidase and eNOS uncoupling, activation of 
Protein kinase C beta II isoform is mostly responsible for NADPH 
oxidase activation and inhibition of eNOS activity [23,33]. Our 
previous studies found that a selective PKC beta II peptide inhibitor 
significantly attenuated oxidative stress in hind limb I/R and restored 
post-reperfused cardiac function in isolated I/R hearts [23,33,34]. 
Given that increased uncoupled eNOS activity facilities oxidative 
stress, the antioxidant and cardioprotective effects of Protein kinase 
C beta II inhibitor most likely are principally due to inhibition on 
NADPH oxidase effects which in turn would reduce oxidation of BH4 
to BH2 and therefore attenuate uncoupled eNOS activity. Therefore, 
understanding vascular/cardiac NADPH oxidase during reperfusion 
following prolonged ischemia may disclose the triggering source of 
oxidative stress in reperfusion injury (Figure 1). Our in vivo and ex vivo 
hind limb and myocardial ischemia/reperfusion models will largely 
exclude the contribution of polymorphonuclear leukocyte NADPH 
oxidase because they are recruited into the reperfusion site after a few 
hours of reperfusion.  
 Apocynin is a selective NADPH oxidase inhibitor that works 
by blocking the association of p47phox with the membrane p22phox 
in endothelial cells and leukocytes [14,35] (Figure 1). Apocynin 
is considered to be a prodrug that is converted to diapocynin by 
endothelial peroxidase and leukocyte myeloperoxidase which then 
oxidizes cysteine-196 on p47phox and thereby inhibits NADPH oxidase 
assembly and activation [22]. P47phox is highly expressed in myeloid and 
vascular smooth muscle/endothelial cells [10]. Therefore, the primary 
target for apocynin would be attenuation of vascular NADPH oxidase 
during ischemia and early reperfusion since only resident PMNs would 
be present during this time. Mozaffari et al. [13] reported that apocynin 
(100 μM) given during pre-ischemia improved + dP/dtmax and + dP/
dtmin and decreased infarct size/area-at-risk compared to untreated 
controls in isolated perfused rat hearts subjected to 40 min regional 
ischemia followed by 2 hour reperfusion [13]. However, their study 
did not measure SO or H2O2 release in the post-reperfused tissue 
to assess the level of reactive oxygen species attenuation induced by 
apocynin to attribute a mechanism of action. Moreover, they did not 
give apocynin exclusively during reperfusion since pretreatment is not 
always a clinical option. Therefore, it is of high clinical importance 
to determine the degree of reactive oxygen species inhibition from 
NADPH oxidase and its relative contribution during the reperfusion 













Figure 4: Representative heart sections of control ischemia/reperfusion, 
ischemia/reperfusion + 40 µM, 400 µM and1 mM apocynin subjected to TTC 
staining. Viable tissue is stained red while the infarcted tissue remained 
unstained (white). The graph shows the ratio of infarcted tissue weight to 
the total tissue weight. Dose-dependent apocynin treatment significantly 
decreased infarct size by 39 ± 7% (40 μM), 28 ± 4% (400 μM) and 29 ± 6% (1 
mM) compared to untreated control myocardial ischemia/reperfusion hearts 
(**p < 0.01).
 
Figure 5: The relative difference in H2O2 release between ischemia/
reperfusion and sham femoral veins during reperfusion in anesthetized rats 
when given saline (n = 7) or apocynin (13.7 mg/kg; n = 6). Apocynin treated 
rats showed a significant reduction in blood H2O2 release compared to saline-
treated controls from 20 min to 45 min of reperfusion (*p < 0.05, **p < 0.01). 
to control ischemia/reperfusion hearts that were 60 ± 5%; 4. Apocynin 
significantly decreased blood H2O2 levels and increased blood NO by 
four-fold compared to saline controls at the end of reperfusion (both, 
p < 0.01). These results suggest that apocynin exerted cardio protective 
effects by inhibiting reactive oxygen species release generated by 
NADPH oxidase during ischemia/reperfusion.
The role of NADPH oxidase and oxidative stress during 
ischemia/reperfusion 
NADPH oxidase activity is increased in myocardial ischemia/
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reported that apocynin reduced SO in cardiac ischemia/reperfusion 
tissue, which was associated with a decrease in infarct size/area-at-
risk compared to controls in mice subjected to regional ischemia for 
30 min followed by 24 hour reperfusion and administered apocynin 
I.V. (5 mg/kg) 10 min prior to reperfusion. However, their study did 
not assess cardiac function or infarct size/area-at-risk, which may be 
associated with the decreased SO release [36]. Similarly, another study 
by Gao et al. [28] also performed regional ischemia in mice for 30 min 
followed by 90 min reperfusion and found that acetylcholine (Ach)-
induced vasodilatation in isolated coronary arterioles was improved in 
mice given apocynin I.V. (25 mg/kg) prior to reperfusion. This effect 
was associated with decreased SO production [28]. Moreover, their 
study attributed the increased NADPH oxidase activity to increased 
TNFα released from vascular smooth muscle in myocardial ischemia/
reperfusion tissue. However, like the Jiao et al. study, Gao et al. study 
did not assess cardiac function or infarct size/area-at-risk. 
Interestingly, apocynin at 1 mM did not improve cardiac function, 
infarct size or area-at-risk compared to the 400 μM dose. It is possible 
that apocynin exerted its maximal effect at 400 μM in the isolated 
perfused heart study. In contrast, the SO release from leukocytes was 
inhibited to a greater extent at 1 mM compared to 400 μM, suggesting 
that vascular and cardiac myocyte NADPH oxidase may have reached 
its maximal inhibition at 400 μM. It is also possible that the 1 mM dose 
may have started to exert some paradoxical oxidative stress in the heart 
tissue.
According to Riganti et. al. [37], apocynin induced oxidative stress 
in a dose-dependent way in glial cells in vitro. Furthermore, high 
concentration apocynin incubated in cultured glial cells showed an 
increase in oxidative stress via measurements of lipid peroxidation, 
H2O2, and cytotoxic level. It should be emphasized that the 
concentration of apocynin used in the hindlimb ischemia/reperfusion 
model (i.e., 13.7 mg/kg) approximated to a concentration of about 
1 mM in blood. However, given that apocynin is a small molecular 
compound that could be cleared by the kidneys, it is plausible that the 
effective dose was less in the blood over time since it took about 20 
minutes for apocynin to exert significant effects on blood H2O2 levels 
and NO levels. Of interest, it should be noted that the initial increase 
in blood H2O2 and NO levels observed in both saline and apocynin-
treated animals is consistent with previous studies showing an initial 
increase in these levels, and may, in part, be due to the initiation of 
blood flow contacting the respective microsensor [4,7,8]. Subsequent 
measurements after this initial burst may more accurately represent the 
relative increase or decrease of the biomolecule being measured (i.e., 
H2O2 or NO).
Conclusion
In summary, apocynin exerted cardio protective effects on post-
refused cardiac function that paralleled a decrease in infarct size/area-
at-risk. Moreover, the reduction of blood H2O2 release and increased 
NO bioavailability in the hind limb ischemia/reperfusion model 
suggests that apocynin exerted its cardio protective effects via the 
inhibition of SO release. Collectively, this study suggests that NADPH 
oxidase significantly contributes to reactive oxygen species production 
during ischemia/reperfusion and that inhibiting this production during 
reperfusion in effective to attenuate oxidative stress and subsequent 
cardiac cell death and cardiac contractile dysfunction. However, it is 
possible that the results of apocynin may in part be due to scavenging 
H2O2 in addition to selective inhibition of NADPH oxidase as suggested 
by Johnson et al. [35].
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